Entries by Andrew Humphreys

,

Reaching Epic Proportions 2013

Click to download the PDF to view the full issue Diabetes Late-Stage Pipeline (Excel Document) One in 10 of the global population will have diabetes by 2035 based on the latest statistics. From 2012 through 2035, the number of people with diabetes is forecasted to rise from 382 million to 592 million. According to the […]

, ,

2nd Annual Review: CNS/Neurology 2013

Click to download the PDF to view the full issue CNS Neurology Awaiting Approval (Excel Document) New Alzheimer’s disease treatments for presymptomatic patients will increase the Ad market size in the years ahead; the multiple sclerosis segment is undergoing a strong growth phase based on the arrival of promising molecules with disease-modifying characteristics and novel […]

Delivering Sustainable Growth 2013

Click to download the PDF to view the full issue J&J emerged from a transitional 2012 continuing to generate annual sales increases and make significant advances on multiple fronts; the company is building out strategic platforms and establishing new ones. Johnson & Johnson constitutes the broadest base of health-care businesses on a global scale. Seventy […]

Strategic Priority Progress 2013

Click to download the PDF to view the full issue A new wave of innovation, productivity, and growth is helping Novartis move past significant patent expirations into the next phase of growth for the company. Novartis capitalized on strong momentum from innovation, growth and productivity throughout 2012 in an effort to offset patent expirations to […]

,

Long Term Strategy 2013

Click to download the PDF to view the full issue Amgen is concentrating on the product pipeline, international expansion, and its entry into the biosimilar market to drive company growth during the years ahead. Amgen executives cited 2012 as an exceptional year for the company. Amgen generated 11 percent revenue growth, 2 percent adjusted earnings […]

13th Annual Feature: Most Admired Companies

Click to download the PDF to view the full issue Johnson & Johnson, Amgen, and Allergan headline the category winners for 2013. The most admired pharma, biotech/biopharma, and specialty company recipients of 2013 – as voted on by the Med Ad News audience – are each former winners whom have reclaimed their respective crowns. After […]